AML1/RUNX1 functions as a cytoplasmic attenuator of NF- B signaling in the repression of myeloid tumors

AML1/Runx1 Negatively Regulates Quiescent Hematopoietic Stem Cells in Adult Hematopoiesis

(2014) M. Ichikawa et al.   JOURNAL OF IMMUNOLOGY

RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis

(2010) S. Schnittger et al.   BLOOD

Identification of AML1-ETO modulators by chemical genomics

(2009) S. M. Corsello et al.   BLOOD

AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations

(2009) J.-L. Tang et al.   BLOOD

Gene discovery in rheumatoid arthritis highlights the CD40/NF-ĸB signaling pathway in disease pathogenesis

(2009) Lindsey A. Criswell   IMMUNOLOGICAL REVIEWS

RUNX1 mutations are frequent in chronic myelomonocytic leukemia and mutations at the C-terminal region might predict acute myeloid leukemia transformation

(2009) M-C Kuo et al.   LEUKEMIA

Cytoplasmic functions of the tumour suppressor p53

(2009) Douglas R. Green et al.   NATURE

AML1 mutations induced MDS and MDS/AML in a mouse BMT model

(2008) N. Watanabe-Okochi et al.   BLOOD

Microenvironment Determines Lineage Fate in a Human Model of MLL-AF9 Leukemia

(2008) Junping Wei et al.   CANCER CELL

Shared Principles in NF-κB Signaling

(2008) Matthew S. Hayden et al.   CELL

Evi-1 Is a Critical Regulator for Hematopoietic Stem Cells and Transformed Leukemic Cells

(2008) Susumu Goyama et al.   Cell Stem Cell